Acquisition, Divestiture, Collaborative Arrangement and Equity-Method Investments - Equity-Method Investments (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended				6 Months Ended						6 Months Ended						6 Months Ended
	Jun. 29, 2014		Jun. 30, 2013		Jun. 29, 2014		Jun. 30, 2013		Jun. 30, 2013 Hisun Pfizer Pharmaceuticals Co. Ltd [Member]	Sep. 06, 2012 Hisun Pfizer Pharmaceuticals Co. Ltd [Member]	Jun. 29, 2014 ViiV Healthcare Limited [Member]	Apr. 01, 2014 ViiV Healthcare Limited [Member]	Mar. 30, 2014 ViiV Healthcare Limited [Member]	Apr. 01, 2014 Glaxosmithkline plc [Member] ViiV Healthcare Limited [Member]	Mar. 30, 2014 Glaxosmithkline plc [Member] ViiV Healthcare Limited [Member]	Sep. 06, 2012 Zhejiang Hisun [Member] Hisun Pfizer Pharmaceuticals Co. Ltd [Member]	Jun. 30, 2013 Indirect retained Interest [Member] Hisun Pfizer Pharmaceuticals Co. Ltd [Member]
Schedule of Equity Method Investments [Line Items]
(Gain) loss associated with the transfer of certain product rights to an equity-method investment	$ 0	[1]	$ 31	[1]	$ 0	[1]	$ (459)	[1]	$ 459								$ 225
Equity method investment, ownership percentage									49.00%	49.00%		11.70%	12.60%	78.30%	77.40%	51.00%
Gain (loss) on disposition of stock in subsidiary or equity method investee											$ 28

[1] In the first six months of 2013, represents the gain associated with the transfer of certain product rights to Hisun Pfizer, our 49%-owned equity-method investment in China. For additional information, see Note 2D. Acquisition, Divestiture, Collaborative Arrangement and Equity-Method Investments: Equity-Method Investments.